CRESCENT BIOPHARMA, INC.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
| Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2025 | Period from September 19, 2024 (Inception) Through September 30, 2024 | |
|---|---|---|---|
| Operating expenses | |||
| Research and development(1) | $20,347 | $43,059 | $2,473 |
| General and administrative(2) | 5,538 | 18,081 | 158 |
| Total operating expenses | 25,885 | 61,140 | 2,631 |
| Loss from operations | (25,885) | (61,140) | (2,631) |
| Other income (expense): | |||
| Interest income | 1,278 | 1,780 | — |
| Interest expense(3) | — | (2,185) | — |
| Total other income (expense) | 1,278 | (405) | — |
| Net loss and comprehensive loss | $(24,607) | $(61,545) | $(2,631) |
| Net loss per share attributable to ordinary shareholders, basic and diluted | $(1.27) | $(7.89) | $(3.60) |
| Net loss per share attributable to Series A non-voting convertible preferred shareholders, basic and diluted | $(1,266.44) | $(7,891.38) | — |
| Weighted-average ordinary shares outstanding used in computing net loss per share to ordinary shareholders, basic and diluted | 16,540,771 | 6,640,402 | 730,092 |
| Weighted-average Series A non-voting convertible preferred shares outstanding used in computing net loss per share to Series A non-voting convertible preferred shareholders, basic and diluted | 2,890 | 1,160 | — |
(1)Includes related party amount of $6,175 and $21,244 for the three and nine months ended September 30, 2025, respectively, and $2,473 for the period from September 19, 2024 (inception) through September 30, 2024.
(2)Includes related party amount of $89 and $719 for the three and nine months ended September 30, 2025, respectively, and $90 for the period from September 19, 2024 (inception) through September 30, 2024.
(3)Includes related party amount of $865 for the nine months ended September 30, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.